Core Viewpoint - The company Huate Dain (000915.SZ) has begun online sales of its children's melatonin product, Manlejing, on platforms such as JD.com and Alibaba, with plans for offline sales in hospitals across China [1] Group 1 - The company reports that its production, operations, and sales are currently normal [1] - The company's stock price fluctuations are influenced by various macroeconomic factors [1] - The company aims to focus on its core business to enhance its competitive strength and deliver good operating results to investors [1]

Group 1 - Nobelpharma's melatonin product, Manlejing®, has been approved for sale in China, specifically for improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marking it as the first melatonin formulation approved for this indication in the country [1][2] - Huate Dain has announced that its subsidiary, Dain Health, has signed an exclusive distribution agreement for Manlejing® in mainland China, with an initial term of 10 years [1][2] - The product was previously launched in Japan in 2020 and has shown significant results in reducing sleep latency in clinical trials [2] Group 2 - Other companies, such as Changchun High-tech and Eifang Pharmaceutical, have already established a presence in the market for treating sleep difficulties associated with neurodevelopmental disorders in children [3] - Huate Dain is a leading player in the children's pharmaceutical health sector in China, with its main revenue and profit sources coming from its subsidiary, Dain Pharmaceutical, which focuses on the development, production, and marketing of children's medications [3]